Showing results (11-20 of 112) with videos related to

Sort By:
Pageof 12
Cancer|May 19, 2012
Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinibJonathan W Goldman, Isett Laux, Feng Chai, et al.
Future Oncology (London, England)|May 7, 2025
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN studyMustafa Özgüroğlu, Jonathan W Goldman, Yuanbin Chen, et al.
Clinical Lung Cancer|March 5, 2023
Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2Yasuhiro Tsutani, Jonathan W Goldman, Sanja Dacic, et al.
Clinical Lung Cancer|July 18, 2017
Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)Daria Gaut, Myung Shin Sim, Yuguang Yue, et al.
Clinical Lung Cancer|May 9, 2025
Brief Report: The Genomic Landscape of Small Cell Lung Cancer in Never-Smoking PatientsMichael S Oh, Edward B Garon, Aaron E Lisberg, et al.
JTO Clinical and Research Reports|March 16, 2023
Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and OsimertinibClayton P Smith, Michael Xiang, Stephanie M Yoon, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 15, 2024
Multiorgan transplant for therapy-associated lung and liver failure in a patient with stage III lung cancerAnitha Chandrasekhar, Hee Chul Yang, Tarik Demir, et al.
Frontiers in Oncology|December 19, 2019
Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung CancerJonathan W Goldman, David M Waterhouse, Ben George, et al.
Drugs in R&D|December 23, 2015
Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid TumorsGerald S Falchook, Xiaofei Zhou, Karthik Venkatakrishnan, et al.
Cancer Chemotherapy and Pharmacology|September 16, 2015
Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancerJohanna C Bendell, Lee S Rosen, Robert J Mayer, et al.
Pageof 12